Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Jun 2

PMID 34070929

Citations 12

Authors

Alice Boileve

Marc Hilmi

Matthieu Delaye

Annemilai Tijeras-Raballand

Cindy Neuzillet

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) and biliary tract cancers (BTC) exhibit a poor prognosis with 5-year overall survival rates around 15%, all stages combined. Most of these primary liver malignancies are metastatic at diagnostic, with only limited therapeutic options, relying mainly on systemic therapies. Treatment modalities are different yet partially overlapping between HCC and BTC. The complex molecular profile of BTC yields to several actionable therapeutic targets, contrary to HCC that remains the field of antiangiogenic drugs in non-molecularly selected patients. Immunotherapy is now validated in the first line in HCC in combination with bevacizumab, while clinical activity of single agent immunotherapy appears limited to a subset of patients in BTC, still poorly characterized, and combinations are currently under investigation. In this review, we provide a critical evaluation and grading of clinical relevance on (i) the main prognostic biomarkers in HCC and BTC, (ii) the main theragnostic biomarkers in both tumors, and lastly (iii) what is recommended in clinical practice.

Citing Articles

Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures.

Sui P, Liu X, Zhong C, Sha Z Sci Rep. 2024; 14(1):10873.

PMID: 38740918 PMC: 11091124. DOI: 10.1038/s41598-024-61629-8.

Therapeutic significance of tumor microenvironment in cholangiocarcinoma: focus on tumor-infiltrating T lymphocytes.

Li C, Bie L, Chen M, Ying J Explor Target Antitumor Ther. 2024; 4(6):1310-1327.

PMID: 38213535 PMC: 10776604. DOI: 10.37349/etat.2023.00199.

Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights.

Yu J, Park R, Kim R J Hepatocell Carcinoma. 2023; 10:1105-1127.

PMID: 37483311 PMC: 10362916. DOI: 10.2147/JHC.S341195.

Histopathological Evaluation and Molecular Diagnostic Tests for Peritoneal Metastases with Unknown Primary Site-a Review.

Bhatt A, Mishra S, Glehen O Indian J Surg Oncol. 2023; 14(Suppl 1):15-29.

PMID: 37359927 PMC: 10284789. DOI: 10.1007/s13193-022-01612-9.

Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study.

Wang Y, Yang X, Wang Y, Xue J, Zhang N, Yang X Cancer Immunol Immunother. 2023; 72(7):2197-2204.

PMID: 36856834 PMC: 10992455. DOI: 10.1007/s00262-023-03399-2.

References

Jung H, Jeong D, Ji S, Ahn T, Bae S, Chin S . Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. Cancer Res Treat. 2016; 49(1):246-254. PMC: 5266389. DOI: 10.4143/crt.2016.066. View

Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M . Genomic spectra of biliary tract cancer. Nat Genet. 2015; 47(9):1003-10. DOI: 10.1038/ng.3375. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Borger D, Tanabe K, Fan K, Lopez H, Fantin V, Straley K . Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2011; 17(1):72-9. PMC: 3267826. DOI: 10.1634/theoncologist.2011-0386. View

Piha-Paul S, Oh D, Ueno M, Malka D, Chung H, Nagrial A . Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020; 147(8):2190-2198. DOI: 10.1002/ijc.33013. View

Abou-Alfa G, Macarulla T, Javle M, Kelley R, Lubner S, Adeva J . Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21(6):796-807. PMC: 7523268. DOI: 10.1016/S1470-2045(20)30157-1. View

Hennedige T, Neo W, Venkatesh S . Imaging of malignancies of the biliary tract- an update. Cancer Imaging. 2015; 14:14. PMC: 4331820. DOI: 10.1186/1470-7330-14-14. View

Zhu A, Kang Y, Yen C, Finn R, Galle P, Llovet J . Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(2):282-296. DOI: 10.1016/S1470-2045(18)30937-9. View

Banales J, Cardinale V, Carpino G, Marzioni M, Andersen J, Invernizzi P . Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016; 13(5):261-80. DOI: 10.1038/nrgastro.2016.51. View

10.

Jorgensen J, Hersom M . Companion diagnostics-a tool to improve pharmacotherapy. Ann Transl Med. 2017; 4(24):482. PMC: 5233535. DOI: 10.21037/atm.2016.12.26. View

11.

Tella S, Kommalapati A, Borad M, Mahipal A . Second-line therapies in advanced biliary tract cancers. Lancet Oncol. 2020; 21(1):e29-e41. DOI: 10.1016/S1470-2045(19)30733-8. View

12.

Razumilava N, Gores G . Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol. 2012; 11(1):13-21.e1. PMC: 3596004. DOI: 10.1016/j.cgh.2012.09.009. View

13.

Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H . Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2013; 59(4):1427-34. DOI: 10.1002/hep.26890. View

14.

Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C, Costentin C . Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. Hepatology. 2016; 64(6):2038-2046. DOI: 10.1002/hep.28710. View

15.

Vogel A, Kasper S, Bitzer M, Block A, Sinn M, Schulze-Bergkamen H . PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study. Eur J Cancer. 2018; 92:11-19. DOI: 10.1016/j.ejca.2017.12.028. View

16.

Negri F, Dal Bello B, Porta C, Campanini N, Rossi S, Tinelli C . Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment. Liver Int. 2015; 35(8):2001-8. DOI: 10.1111/liv.12778. View

17.

Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni J, Cavalloni G, Migliardi G . Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010; 10:631. PMC: 3000850. DOI: 10.1186/1471-2407-10-631. View

18.

Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008; 10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. View

19.

Komuta M, Spee B, Vander Borght S, De Vos R, Verslype C, Aerts R . Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008; 47(5):1544-56. DOI: 10.1002/hep.22238. View

20.

Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B . Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019; 39 Suppl 1:7-18. DOI: 10.1111/liv.14093. View